Interleukin receptor activates a MYD88-ARNO-ARF6 cascade to disrupt vascular stability

Nature

Volumn 492, Issue 7428, 2012, Pages 252-255

  Zhu, Weiquan ^a   London, Nyall R ^a   Gibson, Christopher C ^a,b   Davis, Chadwick T ^a   Tong, Zongzhong ^c   Sorensen, Lise K ^a   Shi, Dallas S ^a   Guo, Jinping ^a,d   Smith, Matthew C P ^a   Grossmann, Allie H ^a   Thomas, Kirk R ^a   Li, Dean Y ^a,e,f  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b Department of Electrical and Computer Engineering   (United States)

^c NAVIGEN INC   (United States)

^d SECOND MILITARY MEDICAL UNIVERSITY   (China)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f SICHUAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE RIBOSYLATION FACTOR 6; ARF NUCLEOTIDE BINDING SITE OPENER; ETANERCEPT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INITIATION FACTOR; INTERLEUKIN 1BETA; INTERLEUKIN RECEPTOR; MYELOID DIFFERENTIATION FACTOR 88; PROTEIN INHIBITOR; SECINH3; UNCLASSIFIED DRUG;

BIODEGRADATION; CELL ORGANELLE; IMMUNE RESPONSE; INFECTIOUS DISEASE; NUMERICAL MODEL; SIGNAL; STABILIZATION;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; BONE DESTRUCTION; CARTILAGE DEGENERATION; CELL ACTIVATION; CELL INTERACTION; CONTROLLED STUDY; CYTOKINE RELEASE; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; EXPERIMENTAL MODEL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INFLAMMATION; INFLAMMATORY CELL; INNATE IMMUNITY; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PERMEABILITY BARRIER; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PROTEIN INTERACTION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM;

ADJUVANTS, IMMUNOLOGIC; ADP-RIBOSYLATION FACTORS; ANIMALS; ARTHRITIS; CADHERINS; CAPILLARY PERMEABILITY; CELL LINE; ENDOTHELIAL CELLS; ENZYME ACTIVATION; GTPASE-ACTIVATING PROTEINS; HUMANS; INTERLEUKIN-1BETA; MYELOID DIFFERENTIATION FACTOR 88; NF-KAPPA B; PROTEIN KINASE INHIBITORS; PROTEIN TRANSPORT; PURINES; RECEPTORS, INTERLEUKIN; SIGNAL TRANSDUCTION; THIOPHENES;

ANIMALIA;

EID: 84870993821     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature11603     Document Type: Article

References (30)

1. Li, Q. & Verma, I. M. NF-kB regulation in the immune system. Nature Rev. Immunol. 2, 725-734 (2002).
2. Collins, T. et al. Transcriptional regulation of endothelial cell adhesion molecules: NF-kB and cytokine-inducible enhancers. FASEB J. 9, 899-909 (1995).
3. Liu, S. F. & Malik, A. B. NF-kB activation as a pathological mechanism of septic shock and inflammation. Am. J. Physiol. Lung Cell. Mol. Physiol. 290, L622-L645 (2006).
4. Rothwarf, D. M. & Karin, M. The NF-kB activation pathway: a paradigm in information transfer from membrane to nucleus. Sci. STKE 1999, RE1 (1999).
5. Pober, J. S. & Sessa, W. C. Evolving functions of endothelial cells in inflammation. Nature Rev. Immunol. 7, 803-815 (2007).
6. Muller, W.A. Leukocyte-endothelial cell interactions in the inflammatory response. Lab. Invest. 82, 521-533 (2002).
7. Royall, J. A. et al. Tumor necrosis factor and interleukin 1 alpha increase vascular endothelial permeability. Am. J. Physiol. Lung Cell. Mol. Physiol. 257, L399-L410 (1989).
8. West, X. Z. et al. Oxidative stress induces angiogenesis by activating TLR2 with novel endogenous ligands. Nature 467, 972-976 (2010).
9. London, N. R. et al. Targeting Robo4-dependent Slit signaling to survive the cytokine storm in sepsis and influenza. Sci. Transl. Med. 2, 23ra19 (2010).
10. Zhu, J. & Mohan, C. Toll-like receptor signaling pathways-therapeutic opportunities. Mediators Inflamm. 2010, 781235 (2010).
11. Kishore, N. et al. A selective IKK-2 inhibitor blocks NF-kB-dependent gene expression in interleukin-1b-stimulated synovial fibroblasts. J. Biol. Chem. 278, 32861-32871 (2003).
12. Matthews, J. S. & O'Neill, L. A. Distinct roles for p42/p44 and p38 mitogenactivated protein kinases in the induction of IL-2 by IL-1. Cytokine 11, 643-655 (1999).
13. Martin, M. U. & Wesche, H. Summary and comparison of the signaling mechanisms of the Toll/interleukin-1 receptor family. Biochim. Biophys. Acta 1592, 265-280 (2002).
14. Kaltschmidt, B., Linker, R. A., Deng, J. & Kaltschmidt, C. Cyclooxygenase-2 is a neuronal target gene of NF-kB. BMC Mol. Biol. 3, 16 (2002).
15. Funk, C. D. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294, 1871-1875 (2001).
16. Palacios, F., Price, L., Schweitzer, J.,Collard, J. G.&D'Souza- Schorey, C.Anessential role for ARF6-regulated membrane traffic in adherens junction turnover and epithelial cell migration. EMBO J. 20, 4973-4986 (2001).
17. D'Souza-Schorey, C., Li, G., Colombo, M. I.&Stahl, P. D.A regulatory role forARF6 in receptor-mediated endocytosis. Science 267, 1175-1178 (1995).
18. Riley, K. N., Maldonado, A. E., Tellier, P., D'Souza-Schorey, C. & Herman, I. M. Betacap73-ARF6 interactionsmodulate cell shape andmotility after injury in vitro. Mol. Biol. Cell 14, 4155-4161 (2003).
19. Zhang, Q. et al. Small-molecule synergist of the Wnt/b-catenin signaling pathway. Proc. Natl Acad. Sci. USA 104, 7444-7448 (2007).
20. Hafner, M. et al. Inhibition of cytohesins by SecinH3 leads to hepatic insulin resistance. Nature 444, 941-944 (2006).
21. Béraud-Dufour, S. et al. A glutamic finger in the guanine nucleotide exchange factor ARNO displaces Mg21 and the b-phosphate to destabilize GDP on ARF1. EMBO J. 17, 3651-3659 (1998).
22. Arend, W. P. Cytokine imbalance in the pathogenesis of rheumatoid arthritis: the role of interleukin-1 receptor antagonist. Semin. Arthritis Rheum. 30, 1-6 (2001).
23. Szekanecz, Z. & Koch, A. E. Vascular involvement in rheumatic diseases: 'vascular rheumatology'. Arthritis Res. Ther. 10, 224 (2008).
24. van den Berg, W. B., Joosten, L. A., Helsen, M. & van de Loo, F. A. Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment. Clin. Exp. Immunol. 95, 237-243 (1994).
25. Joosten, L. A., Helsen, M. M., van de Loo, F. A. & van den Berg, W. B. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNFa, anti-IL-1a/b, and IL-1Ra. Arthritis Rheum. 39, 797-809 (1996).
26. Wooley, P. H., Dutcher, J., Widmer, M. B. & Gillis, S. Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. J. Immunol. 151, 6602-6607 (1993).
27. London, N. R., Whitehead, K. J. & Li, D. Y. Endogenous endothelial cell signaling systems maintain vascular stability. Angiogenesis 12, 149-158 (2009).
28. Keane, J. et al. Tuberculosis associated with infliximab, a tumor necrosis factor a-neutralizing agent. N. Engl. J. Med. 345, 1098-1104 (2001).
29. Lee, W. L. & Slutsky, A. S. Sepsis and endothelial permeability. N. Engl. J. Med. 363, 689-691 (2010).
30. Silva, L. C., Ortigosa, L. C. & Benard, G. Anti-TNF-a agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls. Immunotherapy 2, 817-833 (2010).